Amunix Raises $73M in Series A Financing Back to HomeMOUNTAIN VIEW, CA, Amunix Pharmaceuticals announced the successful completion of an oversubscribed $73M Series A financing.

Amunix Pharmaceuticals, Inc. ("Amunix"), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers, today announced the successful completion of an oversubscribed $73 million Series A financing.

"The completion of our Series A financing marks a critical milestone for Amunix, as the investment affords us a significant financial runway to advance our novel pipeline of T cell engagers and cytokines targeting a spectrum of solid tumors," said Angie You, Ph.D., Chief Executive Officer at Amunix.

Dr. Stampacchia commented, "We are delighted to have successfully led this financing for Amunix, especially in the current market environment.

Schellenberger and You, Amunix's leadership team includes Mika Derynck, M.D., Chief Medical Officer, formerly Global Head for Cancer Immunotherapy, GI/GU Cancers, Angiogenesis Franchises and China Oncology Development at Genentech; Maninder Hora, Ph.D., Chief Technical Operations Officer, formerly Chief Technical Operations Officer at Nektar Therapeutics; Bryan Irving, Ph.D., Chief Scientific Officer, formerly Chief Scientific Officer at Five Prime Therapeutics; and Darcy Mootz, Ph.D., Chief Business Officer, formerly Chief Business Officer of ORIC Pharmaceuticals. | To read full story, visit https://startuparound.com/read/1583416807.2163975/Amunix-Raises-$73M-in-Series-A-Financing?ref=audio_experience